SCHEMBL457794

SCHEMBL457794

CCc1cccc(-c2c[c]c(F)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 1/20 0.47
PTGS2 P35354 1/20 0.43
NOTUM Q6P988 1/20 0.40
IDO1 P14902 1/20 0.40
NISCH Q9Y2I1 1/20 0.39
AGXT P21549 1/20 0.38
FGFR1 P11362 1/20 0.38
TAAR1 Q96RJ0 1/20 0.35
MME P08473 1/20 0.34
CYP17A1 P05093 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
GRIN2B Q13224 2/20 0.34
TP53 P04637 1/20 0.33
PRMT6 Q96LA8 1/20 0.33
TGFBR1 P36897 1/20 0.33
PTPN5 P54829 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL456630 0.81 BCL2 (0.49) BCL2PTGS2NOTUMIDO1NISCH
SCHEMBL15064191 0.81 BCL2 (0.49) BCL2PTGS2NOTUMIDO1NISCH
SCHEMBL454783 0.80 LMNA (0.38) NOTUMNISCHTAAR1TP53
SCHEMBL15064003 0.80 BCL2 (0.47) BCL2PTGS2NOTUMIDO1NISCH
SCHEMBL15063788 0.80 BCL2 (0.47) BCL2PTGS2NOTUMIDO1NISCH
SCHEMBL455812 0.80 BCL2 (0.47) BCL2PTGS2NOTUMIDO1NISCH
SCHEMBL29489424 0.78 BCL2 (0.62) BCL2PTGS2NOTUMIDO1NISCH
SCHEMBL5547358 0.78 BCL2 (0.62) BCL2PTGS2NOTUMIDO1NISCH
SCHEMBL15063856 0.78 BCL2 (0.45) BCL2PTGS2NOTUMIDO1NISCH
SCHEMBL15063924 0.77 ACHE (0.42) NOTUMTP53PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3045450-B1 INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2018-02-07 EP disclosed
EP-3045450-A1 INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS SUMITOMO CHEMICAL CO., LTD. (JP) 2016-07-20 EP disclosed
EP-2614053-B1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF SUMITOMO CHEMICAL CO (JP) 2016-03-23 EP disclosed
US-9040709-B2 Method for producing pyridazinone compounds and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-05-26 US disclosed
US-20140378688-A1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL CO (JP) 2014-12-25 US disclosed
US-8884010-B2 Method for producing pyridazinone compounds and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-11-11 US disclosed
EP-2614053-A1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2013-07-17 EP disclosed
US-20130172556-A1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-07-04 US disclosed
WO-2012033225-A1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172556-A1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF PDXK, DHPS, NQO1 BCL2 3490/4885PTGS2 1335/4885NOTUM 866/4885
US-20140378688-A1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF PDXK, DHPS, NQO1 BCL2 3490/4885PTGS2 1335/4885NOTUM 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.